en · de · es
sermorelin-notes.peptides1126.com › Blog › Receptor Pharmacology And Signalling — What the Evidence Shows

Receptor Pharmacology And Signalling — What the Evidence Shows

By Editorial Desk · published 2025-09-05 · last reviewed 2025-09-28 · Blog

The short version of PT-141 code fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2025-09-28. Anything still debated is marked as such rather than presented as settled.

Receptor Pharmacology And Signalling

Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.

Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.

The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.

Melanocortin Receptor Agonist Pharmacology

Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.

Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.

Pt-141 at a glance

PropertyValueNotes
Primary receptor familyMelanocortin (MC1 to MC5)Agonist activity reported at several subtypes
Signalling pathwayGs, adenylyl cyclase, cyclic AMPCanonical melanocortin signalling route
Backbone lengthSeven amino acidsClassified as a cyclic heptapeptide
Ring closureLactam bridgeConstrains conformation and resists peptidases
Terminal modificationsAcetylated N-terminus, amidated C-terminusReduces breakdown by exopeptidases

Identity and Chemical Background

Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.

PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.

Related pages on this site

Bremelanotide Identity and Background

Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.

Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.

Reference notes

Svarthöna, Bohuslän-Dals svarthöna, or Swedish Black Chicken is a Swedish landrace of domestic chickens that is considered to have originated from Ayam Cemani/Kadaknath breeds of chickens transported from Mozambique to Norway by sailors sometime in the 17th century. The Svarthöna has since adapted to a northerly climate, it but has retained the rare quality of black skin and connective tissue. The current form of Svarthöna has been given the status of a landrace. All Swedish entries in gene banks can be traced to a group of chickens that came to Sweden around the turn of the 19th century. In 1956, this flock was bought by two brothers in Bullarebygd. The Swedish Association for Landrace Breeds has preserved the Svarthöna in a gene bank since 1991. A rooster can weigh up to 2 kg, whilst hens do not exceed 1.5 kg. The eggs are small (38-48 g) with a large yolk. The Svarthöna has some flight ability. The black pigmentation found in skin and connective tissue has been shown to be caused by a variant of the gene EDN3, a trait shared with the Chinese Silkie, Indonesian Ayam Cemani, and Vietnamese Black H'Mong.

Synephrine, or, more specifically, p-synephrine, is an alkaloid, occurring naturally in some plants and animals, and also in approved drugs products as its m-substituted analog known as neo-synephrine. p-Synephrine (or formerly Sympatol and oxedrine [BAN]) and m-synephrine are known for their longer acting adrenergic effects compared to epinephrine and norepinephrine. This substance is present at very low concentrations in common foodstuffs such as orange juice and other orange (Citrus species) products, both of the "sweet" and "bitter" variety. The preparations used in traditional Chinese medicine (TCM), also known as Zhi Shi (枳实), are the immature and dried whole oranges from Citrus aurantium (Fructus Aurantii Immaturus). Extracts of the same material or purified synephrine are also marketed in the US, sometimes in combination with caffeine, as a weight-loss-promoting dietary supplement for oral consumption. While the traditional preparations have been in use for millennia as a component of TCM-formulas, synephrine itself is not an approved over the counter drug. As a pharmaceutical, m-synephrine (phenylephrine) is still used as a sympathomimetic (i.e. for its hypertensive and vasoconstrictor properties), mostly by injection for the treatment of emergencies such as shock, and rarely orally for the treatment of bronchial problems associated with asthma and hay-fever.

Lastly, beta-hydroxyacyl-CoA is oxidized to beta-ketoacyl-CoA while NAD+ is reduced to NADH, which follows the same process as the oxidation of malate to oxaloacetate. In the liver, the carboxylation of cytosolic pyruvate into intra-mitochondrial oxaloacetate is an early step in the gluconeogenic pathway which converts lactate and de-aminated alanine into glucose, under the influence of high levels of glucagon and/or epinephrine in the blood. Here the addition of oxaloacetate to the mitochondrion does not have a net anaplerotic effect, as another citric acid cycle intermediate (malate) is immediately removed from the mitochondrion to be converted into cytosolic oxaloacetate, which is ultimately converted into glucose, in a process that is almost the reverse of glycolysis. In protein catabolism, proteins are broken down by proteases into their constituent amino acids. Their carbon skeletons (i.e. the de-aminated amino acids) may either enter the citric acid cycle as intermediates (e.g. alpha-ketoglutarate derived from glutamate or glutamine), having an anaplerotic effect on the cycle, or, in the case of leucine, isoleucine, lysine, phenylalanine, tryptophan, and tyrosine, they are converted into acetyl-CoA which can be burned to CO2 and water, or used to form ketone bodies, which too can only be burned in tissues other than the liver where they are formed, or excreted via the urine or breath.

As soon as Heseltine was elected in March 1966, the seat of Tavistock was recommended for abolition by the Boundary Commission, divided between the new seats of West Devon (effectively a rural seat, where Heseltine would have had to compete for the candidacy with the sitting MP Peter Mills who had a strong local following) and Plymouth Sutton (which had a strong Powellite/Monday Club element—they eventually selected the right-winger Alan Clark). Several of his activists attempted to persuade him to apply for Plymouth Sutton, but he was not interested, wanting a seat nearer London. In the event, the implementation of the Boundary Review was postponed for partisan reasons until after the next general election by Home Secretary James Callaghan (on the pretext of waiting until after the Redcliffe-Maud Report on local government reorganisation). Heseltine therefore defended Tavistock at the 1970 general election, achieving a better than average swing to the Conservatives.

Sources: en.wikipedia.org

Reference notes

mTOR Complex 2 (mTORC2) is composed of mTOR, rapamycin-insensitive companion of mTOR (RICTOR), MLST8, and mammalian stress-activated protein kinase interacting protein 1 (mSIN1). mTORC2 has been shown to function as an important regulator of the actin cytoskeleton through its stimulation of F-actin stress fibers, paxillin, RhoA, Rac1, Cdc42, and protein kinase C α (PKCα). mTORC2 also phosphorylates the serine/threonine protein kinase Akt/PKB on serine residue Ser473, thus affecting metabolism and survival. Phosphorylation of Akt's serine residue Ser473 by mTORC2 stimulates Akt phosphorylation on threonine residue Thr308 by PDK1 and leads to full Akt activation. In addition, mTORC2 exhibits tyrosine protein kinase activity and phosphorylates the insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) on the tyrosine residues Tyr1131/1136 and Tyr1146/1151, respectively, leading to full activation of IGF-IR and InsR.

==== World War I ==== On the eve of World War I, the Don Cossack Host comprised 17 regular regiments plus 6 detached sotnias (squadrons). In addition two regiments of the Imperial Guard were recruited from the Don territory. By 1916 the Don Host had expanded to 58 line regiments and 100 detached sotnias. The central location of the Don territories meant that these units were employed extensively on both the German and Austro-Hungarian fronts, though less so against the Ottoman Turks to the south. The continued value of the Don and other Cossacks as mounted troops was illustrated by the decision taken in 1916 to dismount about a third of the regular Russian cavalry, but to retain the cossack regiments in their traditional role.

==== Sexual dimorphism ==== In a variety of marine organisms, it is seen that females are larger in size compared to the males in some closely related species. In some lineages, such as the blanket octopus, males become structurally smaller and smaller resembling a term, "dwarfism" dwarf males usually occurs at low densities. The blanket octopus male is an example of sexual-evolutionary dwarfism; females grow 10,000 to 40,000 times larger than the males and the sex ratio between males and females can be distinguished right after hatching of the eggs.

Veneer is obtained either by "peeling" the trunk of a tree or by slicing large rectangular blocks of wood known as flitches. The appearance of the grain and figure in wood comes from slicing through the growth rings of a tree and depends upon the angle at which the wood is sliced. There are three main types of veneer-making equipment used commercially:

=== Interpretation === Accurate interpretation takes a variety of factors into account, such as the thyroid hormones i.e. thyroxine (T4) and triiodothyronine (T3), current medical status (such as pregnancy), certain medications like propylthiouracil, temporal effects including circadian rhythm and hysteresis, and other past medical history.

Sources: en.wikipedia.org

Frequently asked questions

Is PT-141 selective for the MC4 receptor?

It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.

What does the cyclic structure contribute?

The lactam bridge locks the peptide into a defined shape and makes it harder for peptidases to cut the backbone. Terminal blocking groups add further protection at both ends. Together these features extend the molecule's persistence in circulation compared with linear peptides.

What remains unresolved about its site of action?

Evidence from animals favors hypothalamic melanocortin circuits, yet direct confirmation in humans is lacking. A peripheral vascular contribution has also been proposed. How receptor binding translates into a reported behavioral effect is still not mapped.

What is PT-141?

PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.

Network